PURPOSE OF REVIEW: In this era of modern combination antiretroviral therapy (cART) HIV-associated neurocognitive disorders (HAND) continue to affect a large portion of the infected population. In this review, we highlight recent discoveries that help to define the interplay between HIV life cycle, the innate immune system and cellular autophagy in the context of the central nervous system (CNS). RECENT FINDINGS: Investigators have recently elucidated themes in HAND, which place it in a unique framework. Cells of macrophage lineage and probably astrocytes play a role in disseminating virus through the CNS. Each of these cell types responds to a diverse population of constantly evolving virus existing in an inflammatory environment. This occurs though the failure of both host antiviral mechanisms, such as autophagy, and innate immunological signalling pathways to control viral replication. SUMMARY: The newest findings detailed in this review help define why HIV CNS disease is a difficult target for therapeutics and create hope that these new mechanisms may be exploited to attenuate viral replication and eliminate disease.
PURPOSE OF REVIEW: In this era of modern combination antiretroviral therapy (cART) HIV-associated neurocognitive disorders (HAND) continue to affect a large portion of the infected population. In this review, we highlight recent discoveries that help to define the interplay between HIV life cycle, the innate immune system and cellular autophagy in the context of the central nervous system (CNS). RECENT FINDINGS: Investigators have recently elucidated themes in HAND, which place it in a unique framework. Cells of macrophage lineage and probably astrocytes play a role in disseminating virus through the CNS. Each of these cell types responds to a diverse population of constantly evolving virus existing in an inflammatory environment. This occurs though the failure of both host antiviral mechanisms, such as autophagy, and innate immunological signalling pathways to control viral replication. SUMMARY: The newest findings detailed in this review help define why HIV CNS disease is a difficult target for therapeutics and create hope that these new mechanisms may be exploited to attenuate viral replication and eliminate disease.
Authors: R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant Journal: Neurology Date: 2010-12-07 Impact factor: 9.910
Authors: Laurieann Casey Klockow; Hamayun J Sharifi; Xiaoyun Wen; Meg Flagg; Andrea K M Furuya; Michael Nekorchuk; Carlos M C de Noronha Journal: Virology Date: 2013-07-09 Impact factor: 3.616
Authors: Lachlan R Gray; Stuart G Turville; Tina L Hitchen; Wan-Jung Cheng; Anne M Ellett; Hamid Salimi; Michael J Roche; Steve L Wesselingh; Paul R Gorry; Melissa J Churchill Journal: PLoS One Date: 2014-02-28 Impact factor: 3.240
Authors: Irma E Cisneros; Mert Erdenizmenli; Kathryn A Cunningham; Slobodan Paessler; Kelly T Dineley Journal: Neuropharmacology Date: 2018-03-23 Impact factor: 5.250